TCGA-22-1000-01A-01R-A32Z-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
- ANGIOGENESIS+0.520
- COAGULATION+0.520
- ALLOGRAFT_REJECTION+0.500
- COMPLEMENT+0.460
- IL6_JAK_STAT3_SIGNALING+0.460
- INFLAMMATORY_RESPONSE+0.460
- APICAL_JUNCTION+0.450
- INTERFERON_ALPHA_RESPONSE+0.450
- INTERFERON_GAMMA_RESPONSE+0.450
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- E2F_TARGETS-0.590
- MYC_TARGETS_V1-0.550
- G2M_CHECKPOINT-0.520
- DNA_REPAIR-0.370
- OXIDATIVE_PHOSPHORYLATION-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.340
- MTORC1_SIGNALING-0.320
- SPERMATOGENESIS-0.230
- MITOTIC_SPINDLE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.956 |
| 2 | SRR1797296 | — | cohortMD2 | 0.956 |
| 3 | BS_FQX1PRAJ | Neurofibroma | — | 0.954 |
| 4 | SRR8518124 | — | D | 0.949 |
| 5 | BS_ZV9Z3SY6 | pilocytic astrocytoma | — | 0.949 |
| 6 | SRR35579819 | — | A | 0.948 |
| 7 | BS_Z28VKGNS | Neurofibroma | — | 0.948 |
| 8 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.947 |
| 9 | ERR2208937 | — | — | 0.947 |
| 10 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.945 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.640 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| COAGULATION | 0.520 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.460 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.450 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.400 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.360 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |